About

Fineline BioInsights.

The pharmaceutical research and publishing division of Fineline Information & Technology. We produce professional, English-language reports on China’s pharmaceutical industry for a global audience of pharma executives, business development teams and investors.

Why we publish

A pivotal market, poorly documented in English.

Our research is grounded in a simple premise: China has become a pivotal force in the global pharmaceutical innovation supply chain — by 2024, one-third of products introduced by multinational corporations originated from China — yet reliable, source-traced analysis in English remains scarce. Our reports close that gap.

Our flagship

China Pharmaceutical Innovation Archive.

The CPIA is our annual reference report. The 2025 edition distils a full year of China’s pharmaceutical innovation into 52 pages.

01

Regulation & approvals

Regulatory reform and drug approvals — including the first year in which novel drug approvals surpassed 100.

02

Access & payment

Medical insurance negotiations and payment models, and what they mean for pricing and patient access.

03

Deals & IP

Outbound licensing deals at new value highs, and intellectual property protection.

The Archive also traces the transformative journey of China’s pharmaceutical reforms over recent decades, giving readers the institutional context behind today’s market.

Methodology

Every data point traced to a primary source.

We build our analysis from the record itself, not from secondary summaries.

  1. 01

    Regulatory records

    Official regulatory announcements and approval records from the NMPA.

  2. 02

    Policy documents

    Documents from the NHSA and other authorities, including NRDL negotiation outcomes and procurement rules.

  3. 03

    Transaction filings

    Disclosed transaction filings for licensing and cross-border deals.

  4. 04

    Reference base

    A documented reference base of laws, regulations and policy documents spanning four decades of China’s pharmaceutical reform.

We do not publish speculation. Where data is provisional or estimates are used, the report says so.

Editorial team

The people behind the research.

KO

Karia Olsen

Managing Editor

15 years in the pharmaceutical industry. Master’s degree in Pharmacy from Fudan University, and a decade advising multinational clients on China regulatory strategy and market entry.

EZ

Emily Zhang

Design Lead

LZ

Leona Zeng

Production Manager

Copyright & licensing

Company publications.

All reports published under Fineline BioInsights, including the China Pharmaceutical Innovation Archive, are company publications. Copyright is owned by Fineline Information & Technology.

Purchase grants a licence for the buyer’s internal use; redistribution, resale or republication of report content requires written permission. For institutional licensing, please contact us.